Evidence map›Paper›PMID 29721375›Full record

ArticleOncoimmunology

High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion.

Verena Nilius, Madeleine C Killer, Nina Timmesfeld, Melina Schmitt, Roland Moll, Anja Lorch, Jörg Beyer, Elisabeth Mack, Michael Lohoff, Andreas Burchert and 2 more

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Effect ofBiomolecules & biomedicine · 2024
    Article
  2. Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.International journal of molecular sciences · 2023
    Review
  3. Review
  4. Review
  5. B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2022
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Verena NiliusDepartment of Hematology, Oncology and Immunology at the Philipps-University Marburg; Baldinger Strasse, Marburg, Germany.
Madeleine C KillerDepartment of Hematology, Oncology and Immunology at the Philipps-University Marburg; Baldinger Strasse, Marburg, Germany.
Nina TimmesfeldInstitute of Medical Biometry and Epidemiology at the Philipps-University Marburg, Bunsenstrasse 3, Marburg, Germany.
Melina SchmittDepartment of Hematology, Oncology and Immunology at the Philipps-University Marburg; Baldinger Strasse, Marburg, Germany.
Roland MollInstitute of Pathology at the Philipps-University Marburg; Baldinger Strasse, Marburg.
Anja LorchDepartment of Urology at the Heinrich-Heine-University Düsseldorf; Moorenstrasse 5, Düsseldorf, Germany.
Jörg BeyerDepartment of Oncology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland.
Elisabeth MackDepartment of Hematology, Oncology and Immunology at the Philipps-University Marburg; Baldinger Strasse, Marburg, Germany.
Michael LohoffInstitute of Microbiology at the Philipps-University Marburg, Hans-Meerwein Strasse, Marburg, Germany.
Andreas BurchertDepartment of Hematology, Oncology and Immunology at the Philipps-University Marburg; Baldinger Strasse, Marburg, Germany.
Andreas NeubauerDepartment of Hematology, Oncology and Immunology at the Philipps-University Marburg; Baldinger Strasse, Marburg, Germany.
Cornelia BrendelDepartment of Hematology, Oncology and Immunology at the Philipps-University Marburg; Baldinger Strasse, Marburg, Germany.
Philipps University of Marburg · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival of patients with germ-cell cancer (GCC) and primary progression or relapse after cisplatin-based first-line chemotherapy is highly heterogeneous, ranging from close to zero to more than 70%. We investigated β-1,4-Galactosyltransferase-I (

Indexed as

B4GALT1biomarkergerm-cell cancerimmunosurveillanceT-lymphocytes

Identifiers

PMID29721375
PMCPMC5927517
OpenAlexW2782235688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.